A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)

Trial Profile

A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Mocetinostat (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 16 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Aug 2014 Planned number of patients changed from 10 to 20, according to the ClinicalTrials.gov record.
    • 25 Aug 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top